...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Breast Cancer Research and Treatment >Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients
【24h】

Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients

机译：福尔马林固定，石蜡包埋的核心活组织检查中的基因表达模式预测乳腺癌患者中的多西他赛化学敏感性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Previously, we had identified gene expression patterns that predicted response to neoadjuvant docetaxel. Other studies have validated that a high Recurrence Score (RS) by the 21-gene RT-PCR assay is predictive of worse prognosis but better response to chemotherapy. We investigated whether tumor expression of these 21 genes and other candidate genes can predict response to docetaxel. Core biopsies from 97 patients were obtained before treatment with neoadjuvant docetaxel (4 cycles, 100 mg/m2 q3 weeks). Three 10-μm FFPE sections were submitted for quantitative RT-PCR assays of 192 genes that were selected from our previous work and the literature. Of the 97 patients, 81 (84%) had sufficient invasive cancer, 80 (82%) had sufficient RNA for QRTPCR assay, and 72 (74%) had clinical response data. Mean age was 48.5 years, and the median tumor size was 6 cm. Clinical complete responses (CR) were observed in 12 (17%), partial responses in 41 (57%), stable disease in 17 (24%), and progressive disease in 2 patients (3%). A significant relationship (P < 0.05) between gene expression and CR was observed for 14 genes, including CYBA. CR was associated with lower expression of the ER gene group and higher expression of the proliferation gene group from the 21 gene assay. Of note, CR was more likely with a high RS (P = 0.008). We have established molecular profiles of sensitivity to docetaxel. RT-PCR technology provides a potential platform for a predictive test of docetaxel chemosensitivity using small amounts of routinely processed material.
机译：以前，我们已经确定了预测对新辅助多西他赛反应的基因表达模式。其他研究已证实21基因RT-PCR分析的高复发评分（RS）可以预示不良预后，但对化疗的反应更好。我们调查了这21个基因和其他候选基因的肿瘤表达是否可以预测对多西他赛的反应。在接受新辅助多西紫杉醇治疗之前（4个周期，100 mg / m 2 q3周），从97例患者中进行了核心活检。提交了三个10μmFFPE切片，用于从我们以前的工作和文献中选择的192个基因的定量RT-PCR分析。在这97名患者中，有81名（84％）有足够的浸润性癌，80名（82％）有足够的RNA用于QRTPCR分析，有72名（74％）有临床反应数据。平均年龄为48.5岁，中位肿瘤大小为6厘米。观察到临床完全缓解（CR）的12例（17％），部分缓解的41例（57％），稳定疾病的17例（24％）和进行性疾病的2例（3％）。在14个基因（包括CYBA）中观察到基因表达与CR之间的显着关系（P <0.05）。从21基因检测结果来看，CR与ER基因组的较低表达和增殖基因组的较高表达相关。值得注意的是，CR可能具有较高的RS（P = 0.008）。我们已经建立了对多西紫杉醇敏感性的分子概况。 RT-PCR技术为使用少量常规处理的材料进行多西他赛化学敏感性的预测性测试提供了潜在的平台。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号